Research location
Rimini
Italy
Advertisement
Research activity in Rimini
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 102 trials and 105 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rimini
102 linked trials · page 1 of 3Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of TherapyNCT06994377 · 2025-06-25 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245 · 2024-12-03 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingNCT07583485 · 2024-07-01 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 2 site observations
RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)NCT05623319 · 2023-03-27 · 1 site observation
RECRUITING
ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System PacingNCT06324682 · 2023-01-01 · 1 site observation
RECRUITING
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerNCT05896566 · 2024-01-23 · 1 site observation
COMPLETED
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24 · 1 site observation
ACTIVE_NOT_RECRUITING
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerNCT05212701 · 2022-04-19 · 1 site observation
WITHDRAWN
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast CancerNCT05173103 · 2021-09-24 · 1 site observation
COMPLETED
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)NCT05063786 · 2021-09-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Horse-assisted Interventions in an Oncological CentreNCT07831460 · 2021-06-14 · 2 site observations
COMPLETED
Effects of COVID-19 Pandemic on the Outcomes of Colorectal CancerNCT04712292 · 2020-09-08 · 1 site observation
UNKNOWN
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in ItalyNCT04463108 · 2020-06-23 · 1 site observation
COMPLETED
COVID19-hematological Malignancies: the Italian Hematology AllianceNCT04352556 · 2020-04-07 · 1 site observation
UNKNOWN
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)NCT04227327 · 2020-01-07 · 1 site observation
TERMINATED
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · 2019-10-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerNCT03820830 · 2019-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Adjuvant Palbociclib in Elderly Patients With Breast CancerNCT03609047 · 2019-06-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyNCT03860935 · 2019-03-19 · 1 site observation
COMPLETED
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]NCT03734029 · 2018-12-27 · 1 site observation
COMPLETED
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast CancerNCT03595592 · 2018-09-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation
TERMINATED
MEtronomic TrEatment Option in Advanced bReast cAncerNCT02954055 · 2017-09-13 · 1 site observation
COMPLETED
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)NCT03248492 · 2017-08-25 · 1 site observation
TERMINATED
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureNCT03152552 · 2017-07-25 · 1 site observation
TERMINATED
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung CancerNCT03439215 · 2017-06-13 · 1 site observation
UNKNOWN
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsNCT03144947 · 2016-11-29 · 1 site observation
UNKNOWN
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersNCT02869789 · 2016-10-05 · 1 site observation
COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)NCT02727660 · 2016-04-29 · 1 site observation
COMPLETED
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerNCT02633189 · 2016-04-01 · 1 site observation
UNKNOWN
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase ExpressionNCT02919462 · 2016-03-01 · 1 site observation
TERMINATED
OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailureNCT02654587 · 2016-02-12 · 1 site observation
TERMINATED
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaNCT02388048 · 2015-10-01 · 1 site observation
COMPLETED
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · 2015-09-14 · 1 site observation
COMPLETED
Clinical Benefits of the Closed Loop Stimulation in Sinus Node DiseaseNCT02579889 · 2015-09-01 · 1 site observation
TERMINATED
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02352948 · 2015-01-13 · 1 site observation
COMPLETED
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World SettingsNCT02322762 · 2014-12-30 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837 · 2014-12-17 · 2 site observations
ACTIVE_NOT_RECRUITING
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast CancerNCT02308085 · 2014-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)NCT02499614 · 2014-12-01 · 1 site observation
UNKNOWN
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesNCT02238509 · 2014-11-01 · 1 site observation
UNKNOWN
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerNCT02162667 · 2014-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.